

## ASX RELEASE

# Update on Australian breast density screening and reporting

### Highlights:

- **Following a successful trial, BreastScreen SA will use Volpara's AI-based software to inform women of their breast density from 8 August 2023**
- **This is the first time in public breast screening in Australia that all women will be notified of their individual breast density regardless of the density category**
- **BreastScreen QLD is conducting a randomised controlled trial, using Volpara's software, to assess the effect of notifying women participating in population-based breast screening of their breast density**

Wellington, NZ, 08 August 2023: Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX:VHT), a global leader in software for the early detection and prevention of breast cancer, releases this update on breast density screening, noting the recent decision by BreastScreen SA to notify women of their breast density.

"BreastScreen SA's move to notify women screened in the public program of their breast density is a significant development for all women who want to know more about their breast health and the role that breast density can play in both the development and challenges in detecting breast cancer," said Teri Thomas, Volpara CEO and Managing Director. "The use of Volpara's AI-based software to measure breast density in the SA trial gives us encouragement that it may prove useful in other Australian public screening programs, should they move towards breast density notification."

### **BreastScreen SA to report breast density**

For the first time in public breast screening in Australia, all women undergoing mammography in South Australia will be informed of their breast density using Volpara's automated measure from today, 8 August 2023. South Australian women and their GPs will be able to learn their individual breast density following screening at any BreastScreen SA clinic, regardless of density category.

The move to reporting breast density in SA's public screening program follows the conclusion of a six-month research study that BreastScreen SA began in February 2022 at clinics at Arndale, Hyde Park, and a mobile screening unit. The trial measured breast density using Volpara's AI-based software. Volpara's algorithm provides a volumetric measurement of breast tissue from the patient's mammogram data.

A subsequent survey of SA trial participants found that more than 90 percent of respondents wanted to continue to be informed of their breast density. Only two percent preferred not to be told as part of their future appointments. The survey also found that 65 percent of respondents strongly agreed or agreed that knowing their breast density made them feel more informed about making decisions regarding their breast care.

To date, BreastScreen WA has been the only public screening program to notify women and GPs of breast density. However, notification is not for all women and occurs when a mammogram shows a marked increase in breast density.

Elsewhere in Australia, BreastScreen Queensland Sunshine Coast is conducting a randomised controlled trial to assess the effect of notifying women participating in population-based breast screening of their breast density. The BreastScreen Queensland trial is also using AI-based software from Volpara to assess breast density.

### **Breast density notification is already widely available in private practice**

In Australia, Volpara's AI-based software to measure breast density is already deployed at some clinics operated by private breast screening providers, including major radiology groups such as I-MED, Sonic, Lumus, and IDX.

In South Australia, Volpara's customers already include all private practice groups—Radiology SA, Benson Radiology, and Jones Radiology—in addition to all public South Australian Medical Imaging sites. In Western Australia, Perth Women's & Breast Imaging (WBI) has been a Volpara customer for 10 years. Other loyal customers include Imaging Associates, Spectrum Medical Imaging, Wesley Breast Clinic, Sydney Breast Clinic, and North Shore Radiology and Nuclear Medicine.

### **Breast density contributes to breast MRI eligibility**

Interest in breast cancer risk assessment including breast density is growing. In November 2022, eligibility for a Medicare-funded high risk breast MRI in Australia was expanded to women under 60 years of age who have a lifetime risk estimation for breast cancer of greater than 30 percent or a 10-year absolute risk estimation greater than five percent, using the Tyrer-Cuzick algorithm version 8 (TC8). Volpara is the only automated density assessment software measure to be validated for use in TC8.

### **About breast density**

Breast density is one of several risk factors for breast cancer. Dense breast tissue can obscure a tumour when a radiologist interprets a mammogram because both kinds of tissue appear white.

Therefore, having dense breasts reduces mammographic sensitivity and can increase a screening participant's chance of being diagnosed with breast cancer between routine screening mammograms. It is estimated that 25 to 50 percent of women of breast screening age (40 to 74 years) in Australia have dense breasts.

### **Authorisation & Additional Information**

This announcement was authorised by the Chief Executive Officer and Managing Director of Volpara Health Technologies Limited.

### **ENDS**

### **For further information, please contact:**

#### **Corporate Enquiries**

Teri Thomas, CEO & MD

Volpara Health Technologies

[Teri.thomas@volparahealth.com](mailto:Teri.thomas@volparahealth.com)

t: +64 4 499 6029

#### **Investor Relations**

Hannah Howlett

WE Communications

[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

t: +61 4 5064 8064

#### **Media Enquiries**

Trevor Chappell

WE Communications

[tchappell@we-worldwide.com](mailto:tchappell@we-worldwide.com)

t: +61 407 933 437

### **About Volpara Health Technologies Limited (ASX:VHT)**

Volpara Health Technologies makes software to save families from cancer. We help leading healthcare providers have a positive impact on communities around the world. They use Volpara solutions to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions.

Our focus on customer value means that our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.

Volpara is a Certified B Corporation and holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, Volpara has raised A\$132 million. Volpara is based in Wellington, New Zealand, with an office in Seattle.

For more information, visit [www.volparahealth.com](http://www.volparahealth.com)